Meissa Vaccines is a biotech company focused on the advancement and in-licensing of promising vaccine candidates and technology for the prevention of respiratory diseases. If you would like to learn more or have questions, please contact us.
- September 26, 2019. Meissa Vaccines Closes $30 Million Financing to Advance RSV Vaccine into Clinical Trials
- March 27, 2019. Meissa Vaccines Closes $3.4 Million Financing to Advance RSV Vaccine to Clinic
- March 28, 2018. Meissa Vaccines' Cofounder and CEO Dr. Martin Moore to Present at World Vaccine Congress
- August 3, 2017. Meissa Vaccines Announces Seed Round Investment from FundRx
- July 12, 2017. Meissa Vaccines Awarded Fast Track NIH SBIR Grant to Advance IND Preparations for RSV Vaccine Candidate
- May 10, 2017. Meissa Awarded NIH SBIR Grant to Support Development of Multivalent Human Rhinovirus Vaccine Candidate
In the News